Dr. Myers has more than 38 years of industry experience in the drug delivery and specialty pharmaceutical sectors. He previously served as CEO of Innocoll, Inc. and was responsible for taking that company public in 2014. He has also served as president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail) and has held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers has served as a director of Ethicann Pharmaceuticals, a clinical stage pharmaceutical company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company and since 2022 as a director of Cranial Devices, a medical device company.
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic...
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome –...